Enalapril
ACE inibhitor used to treat high blood pressure, diabetic kidney disease, and heart failure.
Enalapril, sold under the brand name Vasotec among others, is an ACE inhibitor medication used to treat high blood pressure, diabetic kidney disease, and heart failure. For heart failure, it is generally used with a diuretic, such as furosemide. It is given by mouth or by injection into a vein. Onset of effects are typically within an hour when taken by mouth and last for up to a day.
Common side effects include headache, tiredness, feeling lightheaded with standing, and cough. Serious side effects include angioedema and low blood pressure. Use during pregnancy is believed to result in harm to the baby. It is in the angiotensin-converting-enzyme (ACE) inhibitor family of medications.
Enalapril was patented in 1978, and came into medical use in 1984. It is on the World Health Organization's List of Essential Medicines.
The public source identifies “Enalapril” as aCE inibhitor used to treat high blood pressure, diabetic kidney disease, and heart failure. This brief keeps that definition visible, then builds a research path around Enalapril, inibhitor and used.
Why this record matters
A short description can identify a subject without explaining its stakes. For “Enalapril”, the useful work is to connect “aCE inibhitor used to treat high blood pressure, diabetic kidney disease, and heart failure” to the records capable of establishing context and consequence.
Named sources, stable identifiers and responsible institutions provide the strongest route from overview to verifiable evidence. The source revision retrieved here is dated Jun 15, 2026. The linked authority identifier is Q422185. None of the 0 selected statements returned an explicit reference. The first chronological checks are 1978 and 1984.
The absence of detail may reflect summary conventions rather than a lack of surviving documentation. The lead is largely declarative, so disagreement and counter-evidence require a deliberate search beyond the opening account. Authority statements aid reconciliation but still require their own references, qualifiers and ranks to be checked.
How to read it
Use the entry as an orientation point, then follow its citations and revision history. Names, dates and institutional relationships should be checked against the original record.
- Subject orientation
- Search vocabulary
- Locating named sources
The closest primary source, responsible institution and strongest cited specialist reference.
Three-step research path
- Establish the record: confirm the title “Enalapril”, its source revision and the description used here.
- Expand the search: follow Enalapril primary sources, Enalapril archive and Enalapril research across catalogues and specialist indexes.
- Test the account: compare the strongest cited source with the responsible institution’s current record and note any disagreement.
Questions for further research
- Which source most directly establishes the central claim about “Enalapril”?
- Which cited source is closest to the event, object or claim?
- Which institution is responsible for the underlying evidence?
Search terms from this dossier
This entry incorporates text from “Enalapril” on English Wikipedia. Contributors are listed in the page history. Text is available under the Creative Commons Attribution-ShareAlike 4.0 License. Selected authority identifiers and statements are retrieved from Wikidata under CC0; their references and qualifiers remain part of the verification path.